insitro, a machine learning-enabled drug discovery and development company, entered three strategic agreements with Lilly focused on advancing potential new medicines for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), based on targets identified using insitro’s AI/ML-based platform.   Current therapies for metabolic diseases primarily manage symptoms without addressing root causes. This collaboration aims to shift this paradigm by combining insi...